Correlation between homocysteine plasma levels and nailfold videocapillaroscopic patterns in systemic sclerosis

Clinical Rheumatology

Volumn 26, Issue 6, 2007, Pages 902-907

  Caramaschi, Paola ^a   Volpe, Alessandro ^a   Canestrini, Sabrina ^a   Bambara, Lisa M ^a   Faccini, Giovanni ^a   Carletto, Antonio ^a   Biasi, Domenico ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Homocysteine; Nailfold videocapillaroscopy; Systemic sclerosis

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTICLE; CAPILLAROSCOPY; CAPILLARY FLOW; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; FINGER BLOOD FLOW; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NAIL BED; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM;

EID: 34250788912     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0425-9     Document Type: Article

References (41)

1. Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042-1050
2. D'Angelo A, Selhub J (1997) Homocysteine and thrombotic disease. Blood 90:1-11.
3. McCully KS (1969) Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111-128
4. Harker LS, Ross R, Slichter SJ, Scott CR (1976) Homocysteine-induced arteriosclerosis. J Clin Invest 58:731-741
5. Rodgers GM, Conn MT (1990) Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 75:895-901
6. Lentz SR, Sadler JE (1991) Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1906-1914
7. Hajjar KA, Mauri L, Jacovina AT et al (1998) Tissue plasminogen activator binding to the annexin II tail domain: Direct modulation by homocysteine. J Biol Chem 273:9987-9993
8. Zhang F, Slungaard A, Vercellotti GM, Iadecola C (1998) Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol 274:R1704-R1711
9. Upchurch GR Jr, Welch GN, Fabian AJ et al (1997) Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272:17012-17017
10. Heinecke JW, Rosen H, Suzuki LA, Chait A (1987) The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262:10098-10103
11. Stamler JS, Osborne JA, Jaraki O et al (1993) Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308-318
12. Majors A, Ehrhart LA, Pezacka EH (1997) Homocysteine as a risk factor for vascular disease: Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 17:2074-2081
13. Petri M (2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9:170-175
14. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH (1996) Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348:1120-1124
15. Fijnheer R, Roest M, Haas FJ, De Groot PG, Derksen RH (1998) Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: A retrospective cohort study. J Rheumatol 25:1737-1742
16. Canataroglu A, Tanriverdi K, Inal T et al (2003) Methylentetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet's disease. Rheumatol Int 23:236-240
17. Okka M, Ozturk M, Kochar MC, Bavbek N, Rasier Y, Gunduz K (2002) Plasma homocysteine level and uveitis in Behçet's disease. Isr Med Assoc J 4(Suppl 11):931-934
18. Lee YJ, Kang SW, Yang JI et al (2002) Coagulation parameters and plasma total homocysteine levels in Behçet's disease. Thromb Res 106:19-24
19. Er H, Evereklioglu C, Cumurcu T et al (2002) Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 86:653-657
20. Martinez-Taboada VM, Bartolome MJ, Fernandez-Gonzales MD, Blanco R, Rodriguez-Valverde V, Lopez-Hoyos M (2003) Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: Influence of corticosteroid therapy. Rheumatology 42:1055-1061
21. Levi Y, George J, Langevitz P et al (1999) Elevated homocysteine levels in patients with Raynaud's syndrome. J Rheumatol 26:2383-2385
22. Marasini B, Casari S, Bestetti A et al (2000) Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. J Rheumatol 27:2621-2623
23. Caramaschi P, Martinelli N, Biasi D et al (2003) Homocysteine plasma level is related to the severity of lung impairment in scleroderma. J Rheumatol 30:298-304
24. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
25. LeRoy EC, Krieg T, Black CM et al (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15:202-205
26. Araki A, Sako Y (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422:43-52
27. Cutolo M, Grassi W, Matucci Cerinic M (2003) Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 48:3023-3030
28. Akesson A, Fiori G, Krieg T, van den Hoogen FHJ, Seibold JR (2002) Assessment of of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 21(Suppl 29):S5-S8
29. Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol 26:2159-2167
30. Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity for systemic sclerosis. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592-598
31. 2-isoprostanes levels in systemic sclerosis: Correlation with clinical features. Rheumatology 45:314-320
32. Riccieri V, Rinaldi T, Spadaro A et al (2003) Interleukin-13 in systemic sclerosis: Relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 22:102-106
33. Valim V, Assis LSS, Simöes MFJ, Trevisani VFM, Puccinelli MLC, Andrade LEC (2004) Correlation between serum E-selectin levels and panoramic nailfold capillaroscopy in systemic sclerosis. Braz J Med Biol Res 37:1423-1427
34. Marasini B, Cugno M, Bassani C, Stanzoni M, Bottasso B, Agostoni A (1992) Tissue-type plasminogen activator and von Willebrand factor plasma levels as marker of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 11:375-382
35. Pignone A, Scaletti C, Matucci-Cerinic M et al (1998) Anti-endothelial cell antibodies in systemic sclerosis: Significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 16:527-532
36. Lunardi C, Bason C, Navone R et al (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6:1183-1186
37. Nelson JL, Furst DE, Maloney S et al (1998) Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351:559-562
38. Herrick AL, Matucci Cerinic M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19:4-8
39. Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35-42
40. Cutolo M, Pizzorni C, Tuccio M et al (2004) Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology 43:719-726
41. Falanga V, Kruskal JB, Franks JJ (1991) Fibrin and fibrinogen-related antigens in systemic sclerosis (scleroderma). J Am Acad Dermatol 25:771-775